This conference is useful to my current role because...

"I am new in the antibody therapeutic field and this conference provides significant amounts of valuable information to me." - Ulrik Lademann, Senior Scientist, Symphogen

"It keeps me abreast of knowledge and technology that will impact research." - Ray Camphausen, Assistant Vice President, Adnexus, a Bristol-Myers Squibb R&D Co

"I engineer recombinant Ab for therapeutic purposes for cancer infection and neurodegenerative diseases." - Jamshid Tanha, Research Officer, National Research Council Canada

"I am trying to broaden my knowledge of new technology in a new area" - Mark Federspiel, Associate Professor, Mayo Clinic

"It gives an overview of the most up-to-date developments in the field. - Stanislas Blein, Dy Director, Glenmark Pharmaceuticals Sa

What I like most about this conference is...

"The keynote presentations and the presentation of recently obtained results." - Ulrik Lademann, Senior Scientist, Symphogen

"The opportunity to network, seeing timely presentations, and the opportunity to present own work." - Ray Camphausen, Assistant Vice President, Adnexus, a Bristol-Myers Squibb R&D Co

"The sort of new ideas and new techniques." - Marcelo de Macedo Brígido, Full Professor, Centro de Apoio ao Desenvolvimento Tecno

"It covers basic and applied topics, provides world class researchers in the field, and of course the location!" - Jamshid Tanha, Research Officer, National Research Council Canada

"The combined cause of antibody therapeutics and antibody engineering; knowing the whole pipeline". - Mark Federspiel, Associate Professor, Mayo Clinic

"That antibody therapeutics really bridges engineering and preclinical/clinical together." - Stanislas Blein, Dy Director, Glenmark Pharmaceuticals Sa

I found this course worthwhile because...

"The conference provided a number of potential solutions to issues with my line of work." - Faisal Malik, Research Associate, Agensys Inc

"This pre-conference course was an excellent high level A to Z description of what is involved in the production of biologics." - Paula Lario, Lead Scientist, Protein Engineering, Zymeworks

"I have 12 years in industry and a business degree. I have had little exposure to the MFS function. Now I will be able to better do my job because I understand the whole MFS process. " - Stacey Hixson, Quality Product Owner, Baxter Healthcare Corporation

"This pre-conference course was a succinct and informative course that was well worth attending." - Adam Corper, Scientist in Protein Engineering, Zymeworks Inc

What was the main reason you attended this conference?

"I attended this conference to present our mAb CRB0017 and to see news in the mAb world." - Gianiranco Caselli, Rottapharm SpA

"The main reason I attended this conferences was because it is the best conference in antibody engineering and therapy!" - Carlos Barbas, Kellogg Professor, Scripps Research Institute

"To make contacts and understand how and where the field is moving." - Josee Golay, Group leader, Ospedali Riunit

"To become aware of the current state of the Ab engineering community which was met." - Ashley Meyers, Research Associate, University of Guelph

"To get an update on the therapeutic antibody field." - Mats Persson, Associate Professor, Karolinska Institutet

"To learn about recent developments in antibody engineering and therapeutics." - Estelle Leclerc, Assistant Professor, NDSU

"The main reason I attended this conference was because everyone else does!" - Bob Ladner, Chief Technical Officer, Dyax Corporation

"To present a poster, network, and gain a better understanding of the state of the antibody R&D community; all these objectives were met. " - Jillian Tarling, University of Guelph

"To assess new developments in Ab engineering technology." - Shemy LaPorte, Senior Scientist, Cytomx

"For information on current antibodies, bispecific, and ADLs; this objective was met. - Rebecca Croasdale, Scientist, Roche Diagnostics GmbH

"To present at Ab Engineering, learn about immunomodulators mabs in clinic, and learn the latest on bispecific/multi specific mabs in development. All of these objectives were met." - John Lambert, EVP, R&D and Chief Scientific Officer, ImmunoGen

"I was invited to give an overview on amyloid beta immunotherapy for Alzheimer's disease." - Cynthia Lemere, Associate Professor of Neurology, Harvard Medical School

"To obtain new information on antibody engineering for diagnostic purposes. - Jason White, Graduate Student Researcher, University of California, Davis

"For an update on the most recent advances in this field. - Massimo Masiero, Post Doctorate, Oxford Brookes University

"The main reason I attended this conference was for partnership." - John Zhang, Director, Plexera

"For education, being new to the field, to enjoy the mix of basic science lectures which helped explained results observed in the clinic, and to enjoy the clinical trial results."

"To hear about the latest developments in the antibody field, pre-clinic and clinic." - Gordana Wozniak-Knopp, Senior Post-Doc, F-Star

"To identify emerging topics in Antibody research. - Pierre-Francois Berne, Group Leader, Sanofi Aventis R&D

"To find an update on product technology in mAb and meet people in this field. - Jerome Tiollier, Chief Development Officer, Innate Pharma

"To gain appreciation for the current scope of mAb field and to network with colleagues in the field of medti-specifics." - David Hilbert, Chief Scientific Officer & Head R&D, Zyngenia

"The main reason I attended this conference was to learn Ab engineering techniques and applications". - Holly Jing, CSO, 3DBio